NFKB1 and breast carcinoma: Previous studies have shown that silibinin can prevent the activation of MAPKs and NF-κB in different cell types and signaling pathways, such as osteoclast precursor cells, thyroid and breast cancer cells, and gastric cancer cells [29,30,31,32].